Effect of Early Administration of TXA in Adult Hip Fractures

Condition(s) studied

Investigational drug(s) / intervention(s)

Tranexamic acid: TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups

Study summary

This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.

Eligibility

Primary outcome measure(s)

• Postoperative Blood Transfusion — Up to two weeks
  Patient receives a blood transfusion during their postoperative stay in the hospital
• Overall Blood Loss — Up to two weeks
  Calculate the difference in postoperative blood loss between groups

Trial sites (1)

More Ascension Health trials in the USA